Sugi Predict

Sugi Predict / Compounds / SCHEMBL7518490

SCHEMBL7518490

SCHEMBL7518490

NN1C=CC=Cc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SCN4A P35499 1/20 0.39
▸ SCN5A Q14524 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ P2RX4 Q99571 10/20 0.34
▸ P2RX1 P51575 4/20 0.34
▸ P2RX3 P56373 4/20 0.34
▸ P2RX7 Q99572 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ GRIN1 Q05586 1/20 0.30
▸ GRIN2A Q12879 1/20 0.30
▸ GRIN2B Q13224 1/20 0.30
▸ PTBP1 P26599 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312853 0.76 LMNA (0.41) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL8769693 0.74 LMNA (0.35) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL1246144 0.74 LMNA (0.39) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL7414781 0.74 LMNA (0.35) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL9030868 0.74 LMNA (0.35) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL1248885 0.74 LMNA (0.35) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL1249107 0.74 MTNR1A (0.39) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL20987115 0.72 MAPK1 (0.35) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL3691734 0.71 LMNA (0.55) LMNATSHRMAPK1SCN4ASCN5A
SCHEMBL3732224 0.71 P2RX4 (0.35) LMNATSHRMAPK1SCN4ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BOLT BIOTHERAPEUTICS, INC. (US) 2026-03-10 — — US claimed
US-20250263392-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2025-08-21 — — US claimed
US-20240033370-A1 ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2024-02-01 — — US claimed
CN-116723866-A anti-PD-L1 immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2023-09-08 — — CN claimed
US-20220315537-A1 MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS BOLT BIOTHERAPEUTICS, INC. (US) 2022-10-06 — — US claimed
CN-114585390-A Aminobenzazepine compounds, immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2022-06-03 — — CN claimed
EP-3983082-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF Bolt Biotherapeutics, Inc. (US) 2022-04-20 — — EP claimed
EP-3983080-A1 MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS Bolt Biotherapeutics, Inc. (US) 2022-04-20 — — EP claimed
CN-113164618-A Methods and compositions for treating diseases with immunostimulatory conjugates 希沃尔拜克治疗公司 2021-07-23 — — CN claimed
EP-3849615-A1 COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES Silverback Therapeutics, Inc. (US) 2021-07-21 — — EP claimed
US-20200390899-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2020-12-17 — — US claimed
WO-2020252294-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2020-12-17 — — WO claimed
WO-2020252254-A1 MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS BOLT BIOTHERAPEUTICS, INC. (US) 2020-12-17 — — WO claimed
US-20200113912-A1 Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates SILVERBACK THERAPEUTICS, INC. (US) 2020-04-16 — — US claimed
WO-2020056008-A1 COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES SILVERBACK THERAPEUTICS, INC. (US) 2020-03-19 — — WO claimed
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BOLT BIOTHERAPEUTICS, INC. (US) 2026-03-10 — — US disclosed
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BOLT BIOTHERAPEUTICS, INC. (US) 2026-03-10 — — US disclosed
EP-0734398-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 1997-04-16 — — EP disclosed
EP-0734398-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1996-10-02 — — EP disclosed
WO-1995016712-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1995-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263392-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF IDO2, IDO1, BCR LMNA 3784/4885TSHR 3812/4885MAPK1 4131/4885
US-20200113912-A1 Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates CD74, CD47, CD69 LMNA 4247/4885TSHR 1563/4885MAPK1 4448/4885
US-20220315537-A1 MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS CCNB1, CCNB2, MUS81 LMNA 1067/4885TSHR 4311/4885MAPK1 3619/4885
US-20200390899-A1 AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF IDO2, IDO1, BCR LMNA 3784/4885TSHR 3812/4885MAPK1 4131/4885
US-20240033370-A1 ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF PDCD1LG2, CD274, PDCD1 LMNA 2819/4885TSHR 2792/4885MAPK1 2280/4885
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BCL6, CLTB, MET LMNA 432/4885TSHR 1278/4885MAPK1 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.